GLP1R and metabolic syndrome: Statistical analysis of the differential characteristics between Cohort 1 and Cohort 2 revealed significant differences (P < 0.05) in the following variables: age, sex, FBG, HbA1c, low-density lipoprotein (LDL), lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), body mass index (BMI), glucagon-like peptide-1 receptor agonist (GLP-1RA) use, glinide use, hyperlipidemia, obesity, metabolic syndrome, and major adverse cardiac events (MACE) (Figure 5).